NCT01752491View on ClinicalTrials.gov

A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 1, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 15, 2019

Conditions
GlioblastomaGBMGlioblastoma Multiforme
Interventions
DRUG

Ascorbate

Intravenous infusion of high-dose ascorbate

DRUG

Temozolomide

Oral chemotherapeutic

RADIATION

Radiation therapy

External beam radiation therapy

Trial Locations (1)

52242

Holden Comprehensive Cancer Center at the University of Iowa, Iowa City

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Joseph J. Cullen, MD, FACS

OTHER

NCT01752491 - A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter